Естонија - Естонски - Ravimiamet

aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk; 20mg 60tk; 20mg 100tk; 20mg 10tk; 20mg 98tk; 20mg 50tk; 20mg 28tk; 20mg 20tk; 20mg 7tk

Естонија - Естонски - Ravimiamet

teva b.v. - paroksetiin - õhukese polümeerikattega tablett - 20mg 20tk; 20mg 100tk; 20mg 60tk

Естонија - Естонски - Ravimiamet

hexal ag - paroksetiin - õhukese polümeerikattega tablett - 20mg 30tk; 20mg 28tk; 20mg 20tk; 20mg 100tk

Естонија - Естонски - Ravimiamet

aurobindo pharma limited - paroksetiin - õhukese polümeerikattega tablett - 30mg 30tk; 30mg 100tk; 30mg 250tk; 30mg 14tk; 30mg 50tk; 30mg 28tk; 30mg 10tk; 30mg 20tk; 30mg 98tk; 30mg 56tk

Естонија - Естонски - Ravimiamet

hexal ag - paroksetiin - õhukese polümeerikattega tablett - 40mg 100tk; 40mg 20tk; 40mg 30tk; 40mg 14tk

Естонија - Естонски - Ravimiamet

orion corporation - paroksetiin - õhukese polümeerikattega tablett - 20mg 60tk; 20mg 100tk; 20mg 20tk; 20mg 30tk

Естонија - Естонски - Ravimiamet

sanofi b.v. - küüliku anti-t-lümfotsüütne immunoglobuliin - infusioonilahuse pulber - 25mg 1tk

Естонија - Естонски - Ravimiamet

laboratorios hipra s.a. - sigade inaktiveeritud parvoviirusvaktsiin - süsteemulsioon - 2560hai.u 1annus 10annus 1tk

Европска Унија - Естонски - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Европска Унија - Естонски - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.